News
Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.
Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.
Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...
Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results